back to vol. 16, b. 3, 2010
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2010, vol. 16, book 3
Subject Collection: Medicine
Page: 3 - 7
DOI: 10.5272/jimab.1632010_3-7
Online date: July 05, 2010

J of IMAB 2010; 16(3):3-7
Maria Kazakova1, Tanya Deneva2, Vanya Uzunova3, Victoria Sarafian1
1) Department of Medical Biology; 2) Department of Clinical Laboratory; 3) Clinic of Thoraco-Abdominal Surgery;
Medical University - Plovdiv, Bulgaria.

YKL-40, also known as human cartilage glycoprotein 39, is a member of the “mammalian chitinase-like proteins”, but lacking of chitinase activity. Increased variations in serum concentrations are associated with inflammatory processes and several types of cancer.
In this study we evaluated serum YKL-40 levels in healthy controls and in women with benign and malignant breast tumors.           
YKL-40 serum levels were measured by enzyme-linked immunosorbent assay – ELISA in 32 patients. The effect of the various factors was analyzed using correlation and regression analyses simultaneously determining the size and direction of correlation. The level of statistical significance of null hypothesis was P<0.05. 
Our study showed that serum YKL-40 level in breast carcinoma was significantly higher than the concentration in healthy controls (p<0.01). The changes in protein levels were higher than 25%. Serum YKL-40 increased with age (rxy=0.46). The correlation between glycoprotein quantity and age was positive, but feeble.
This investigation is first in Bulgaria to demonstrate significantly elevated serum YKL-40 level in breast carcinoma compared to women with benign breast tumors and healthy controls. Longitudinal studies are needed to confirm YKL-40 as a potential and reliable biomarker.

Key words: YKL-40, ELISA, breast tumor.

- Download FULL TEXT /PDF 199 KB/
Please cite this article as: Kazakova M, Deneva T, Uzunova V, Sarafian V. YKL-40 IN SERA OF BREAST TUMOR PATIENTS. J of IMAB. 2010; 16(3):3-7. doi: 10.5272/jimab.1632010_3-7.

1. Jensen BV, Johansen JS, Price PA. High levels of serum HER-2/neu and YKL- 40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res, 2003; 9: 4423-4434.[ PubMed ]
2. Qin W, Zhu W, Schalter L., et al. Increased expression of the inflammatory protein YKL-40 in precancers of the breast. Int  J  Cancer, 2007; 121: 1536–1542.[ CrossRef ]
3. Zhong L, Ge K,  Zu J., et al. Autoantibodies as potential biomarkers for breast cancer. Breast Cancer Res, 2008; 10:[ CrossRef ] [ PubMed ]
4. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem, 1993; 268: 25803-25810.
5. Hogdall EVS, Johansen JS, Kjaer SK., et al. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep, 2003; 10: 1535-1538.
6. Hogdall E, Ringsholt M, Hogdall C., et al. YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer, 2009; 9: 8 doi: 10.1186/1471-2407-9-8[ CrossRef ]
7. Dupont J, Tanwar MK, Thaler HT., et al. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol, 2004; 22: 3330-3339.[ CrossRef ]
8. Cintin C, Johansen JS, Christensen IJ., et al. Serum YKL-40 and colorectal cancer. Br J Cancer, 1999; 79: 1494-1499.[ CrossRef ] [ Medline ]
9. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res, 2002; 62: 4364-4368. [PubMed ]
10. Hormigo A, Gu B, Karimi S., et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res, 2006; 12: 5698-5704.[ CrossRef ]
11. Schmidt H,  Johansen JS,  Gehl J., et al. Elevated serum levels of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer, 2006; 106: 1130-1139. [PubMed ]
12. Volck B, Johansen JS, Stoltenberg M., et al. Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage, 2001; 9: 203-214.[ CrossRef ] [ Medline ]
13. Johansen JS. Studies on serum YKL-40 as a bioarker in diseases with inflammation, tissue emodelling, fibroses and cancer. Dan Med Bull, 2006; 53:172-209. [ Medline ]
14. Kawazaki M, Hasegawa Y, Kondo S., et al. Concentration and localization f YKL-40 in hip joint diseases. J Rheumatol, 2001; 28: 341-345.
15. Zivanovic. S, Rachov LP, Vojvodic D, Yucetie D. Human cartilage glycoprotein 39 – biomarker of joint damage in knee osteoarthritis. International Orthopaedics, 2009, 33: 1165-1170.
16. Vind I, Johansen JS, Price PA, Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol, 2003; 38: 599-605.[ Medline ]
17. Johansen JS, Baslund B, Garbarsch C., et al. YKL-40 in giant cells and macrophages from patients with giant cell artheritis. Arthritis Rheum, 1999; 42: 2624-2630.
18. Johansen JS, Milman N, Hansen M., et al. Increased serum YKL-40 in patients with pulmonary sarcoidosis. A potential marker of disease activity? Resp Med, 2005; 99: 396-402.[ PubMed ]
19. Nrjgaard C, Johansen JS, Christensen E., et al. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol, 2003, 39: 179-186.
20. Johansen JS, Lottenburger T, Nielsen HJ., et al. Weekly and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol Biomarkers Prev, 2008;  5: 2603:2608.
21. Johansen JS, Hryer PE, Larsen LA, et al. YKL-40 protein expression in the early developing human musculoskeletal system. J Histochem Cytochem, 2007; 55: 1213-1128.
22. Ringsholt M, Hrgdall EVS, Johansen JS., et al. YKL-40 protein expression in normal adult human tissues - an immuno­histochemical study. J Mol Hist, 2007; 38: 33–43.
23. Bruunsgaard H, Pedersen M, Pedersen BK. Aging and proinflammatory cytokines. Curr Opin Hematol, 2001; 8: 131-136. [ PubMed ]
24. De Ceuninck F, Gaufillier S, Bonnaud A., et al. YKL-40 (Cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun, 2001; 285: 926-931. [ CrossRef ] [ Medline ] [ Web of Science ]
25. Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J, 2002; 365: 119-126. [ Medline ]
26. Mohanty AK, Singh G, Paramasivam M., et al. Crystal structure of a novel regulatory 40-kDa mammary gland protein (MGP-40) secreted during involution. J Biol Chem, 2003; 278: 14451-14460.
27. Roslind A, Johansen JS. YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol, 2009; 511: 159-184.
28. Cintin C, Johansen JS, Christensen IJ., et al. Highserum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer,  2002; 95: 267-74. [ PubMed ]
29. Johansen JS, Jensen BV, Roslind A, et al. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev,  2006; 15: 194-202. [ PubMed ]
30. Ringsholt M, Hogdall EVS, Johansen JS., et al. YKL-40 protein expression in normal adult human tissues – an immunohistochemical study. J Mol Hist, 2007; 38: 33–43.
31. Yamac D, Ozturk B, Coskun U., et al.  Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer. Advance in Therapy, 2008; 25: 801-809. [ PubMed ]
32. Shao R, Hamel K, Petersen L., et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene, 2009; 28: 4456-4468. [ PubMed ]

back to Online Journal